Wikipedia

Global AMR R&D Hub

The Global Antimicrobial Resistance Research and Development Hub (hereafter referred to as the Hub) is an international organization initiated under the auspices of the German G20 presidency. The Hub was established to support global coordination in antimicrobial resistance (AMR), or drug resistance, which the World Health Organization has identified as one of the top global health threats, with a particular focus on research and development (R&D).[2][3][4][5]

Global Antimicrobial Resistance Research and Development Hub
Formation2017; 9 years ago (2017)[1]
Founders
TypeInternational organization
PurposeGlobal health, Antimicrobial resistance, Research and development
HeadquartersBerlin, Germany
Region served
Worldwide
Members22
Key people
  • Lesley Ogilvie (Director)
  • Ralf Sudbrak (Deputy Director)
Websiteglobalamrhub.org

Launched in May 2018, the Hub operates with a Secretariat based in Berlin, supported by the German government. It is guided by a Board of Members, comprising representatives from 19 countries, the European Commission, Gates Foundation, and Wellcome Trust, along with five Observers, including WHO, FAO, OECD, WOAH, and Africa CDC,[6] and a Stakeholder Group representing a broad spectrum of interests from academia, industry, funding bodies, and civil society.[7]

The Hub focuses on strengthening research and development efforts and promoting sustainable investment in the AMR field through a One Health approach. Its activities include coordinating international initiatives, supporting innovation, and improving the alignment of investments in AMR R&D. AMR experts have described the Hub as a mechanism for coordinating international responses to AMR.[8][9]

Activities

edit

The Global AMR R&D Hub's activities focus on promoting AMR research and development. These activities are structured around three core pillars, which collectively aim to streamline global efforts against AMR.

Advocacy and Policymaker Engagement

edit

The Hub engages with policymakers by providing up-to-date analysis and information on AMR R&D.

Its data and analyses have been featured in several high-level reports, including those prepared for G7 Finance and Health Ministers in collaboration with the WHO, which assess progress in strengthening the AMR R&D pipeline,[10][11] as well as in publications of the Global Leaders Group on Antimicrobial Resistance,[12] and have been cited in major media outlets, including Politico[13] and Germany's Tagesspiegel.[14]

The Hub has participated in discussions on AMR R&D at high-level fora such as the United Nations General Assembly,[15] Germany's Parliamentary Group on Antimicrobial Resistance (PKAMR),[16] Tokyo AMR One-Health Conference,[17] among others.

Since its establishment, the Hub has been referenced in G20 outcome documents under every presidency, including Leaders’ Declarations, ministerial communiqués, and Chair’s summaries; several of these documents also acknowledge or support its role.[18][19][20][21][22][23][24][25][26]

Support Evidence-based Decision Making

edit

The Hub provides data on AMR R&D activities and funding through its Dynamic Dashboard, which is used by policymakers, researchers, and private sector stakeholders to assess ongoing initiatives and identify gaps.[27][28][29][30][31]

The Hub has highlighted the role of both "push" and "pull" incentives in supporting AMR R&D. These incentives are designed to stimulate R&D activities, by reducing costs and risks ("push") and rewarding successful outcomes ("pull"), as mechanisms to support research and development activities.[32]

Encouraging Collaboration

edit

The Hub facilitates collaboration among international stakeholders involved in AMR R&D. This includes engagement with public, private, and academic partners.[33] For instance, the former Director General for Vaccines and Therapeutic Readiness at the Public Health Agency of Canada noted that the data and collaboration provided by the Hub helped shape "Canada's Antibiotic Access Pilot Project". It also collaborates with academic institutions such as the Institute of Urban Environment at the Chinese Academy of Sciences to apply advanced technologies, including artificial intelligence, in analysing the AMR R&D landscape.

An external evaluation of the Global AMR R&D Hub's activities between 2018 and 2021, conducted by the European research and policy analysis centre PPMI, concluded that "the Hub achieved considerable progress towards its objectives during its first three years of operation".[34]

References

edit
  1. ↑ "History".
  2. ↑ World Health Organization (2023), Antimicrobial resistance, World Health Organization
  3. ↑ Green, Andrew (2017), Inside Germany's push for a global anti-microbial resistance hub, Devex
  4. ↑ Renwick, Matthew; Mossialos, Elias (2020), Fostering R&D of novel antibiotics and other technologies to prevent and treat infection, Cambridge University Press
  5. ↑ Mattar, Caline; Edwards, Suzanne; Baraldi, Enrico; Hood, Jennie (2020), An overview of the global antimicrobial resistance research and development hub and the current landscape
  6. ↑ https://globalamrhub.org/board-of-members/
  7. ↑ Mattar, Caline; Edwards, Suzanne; Baraldi, Enrico; Hood, Jennie (2020), An overview of the global antimicrobial resistance research and development hub and the current landscape
  8. ↑ Anderson, Michael; Chatterjee, Anuja; Clift, Charles; Mossialos, Elias (2020), Introduction (PDF), Cambridge University Press
  9. ↑ Burki, Talha Khan (2018), A new alliance joins the fight against antimicrobial resistance, The Lancet Respiratory Medicine
  10. ↑ Jesudason, Timothy (2023), Maintaining a robust pipeline of antibiotics, The Lancet Infectious Diseases
  11. ↑ World Health Organisation (2024), New WHO report presents progress in G7 countries in tackling antibiotic pipeline crisis, World Health Organisation
  12. ↑ Global Leaders Group on Antimicrobial Resistance (2023), Information Note on Financing for Antimicrobial Resistance / Note d'information sur le financement de la résistance aux antimicrobiens (PDF), Global Leaders Group on Antimicrobial Resistance
  13. ↑ Politico (2024), These are the most deadly pathogens — so why aren't drug companies targeting them?, Politico
  14. ↑ Göpel, Gunnar (2024), Neben neuen Antibiotika braucht es neue Impfstoffe, Taggespiegel
  15. ↑ One Health Trust (2024), Highlights from the 79th United Nations General Assembly Week – A critical time for global action to tackle AMR, One Health Trust
  16. ↑ German Centre for Infection Research (2026), Equitable access to innovative antibiotics—global challenges and policy options, German Centre for Infection Research
  17. ↑ Ministry of Health, Labour and Welfare of Japan (2025), Summary of Tokyo AMR One Health Conference 2025 (PDF), Ministry of Health, Labour and Welfare of Japan
  18. ↑ G20 Germany (2017), G20 Leaders' Declaration: Shaping an Interconnected World, G20{{citation}}: CS1 maint: numeric names: authors list (link)
  19. ↑ G20 Argentina (2018), Declaration of the G20 Meeting of Health Ministers (PDF), G20{{citation}}: CS1 maint: numeric names: authors list (link)
  20. ↑ G20 Japan (2019), Okayama Declaration of the G20 Health Ministers (PDF), G20{{citation}}: CS1 maint: numeric names: authors list (link)
  21. ↑ G20 Saudi Arabia (2020), G20 Health Ministers' Meeting Statement, G20{{citation}}: CS1 maint: numeric names: authors list (link)
  22. ↑ G20 Italy (2021), Declaration of the G20 Health Ministers (PDF), G20{{citation}}: CS1 maint: numeric names: authors list (link)
  23. ↑ G20 Indonesia (2022), Chair's Summary: G20 Health Ministers' Meeting (PDF), G20{{citation}}: CS1 maint: numeric names: authors list (link)
  24. ↑ G20 India (2023), G20 Health Ministers' Meeting Outcome Document and Chair's Summary (PDF), G20{{citation}}: CS1 maint: numeric names: authors list (link)
  25. ↑ G20 Brazil (2024), G20 Health Working Group Ministerial Declaration (PDF), G20{{citation}}: CS1 maint: numeric names: authors list (link)
  26. ↑ G20 South Africa (2025), G20 Health Ministers' Chair's Statement (PDF), G20{{citation}}: CS1 maint: numeric names: authors list (link)
  27. ↑ Evans, Eric J.; Meyer, Alexandre; Conti, Rena M. (2024), Sizing A Market Entry Reward for the Development of New Antibiotics, Mossavar-Rahmani Center for Business & Government, Harvard University
  28. ↑ Årdal, Lacotte Yohann; Edwards, Suzanne; Poloy, Marie-Céline (2021), National Facilitators and Barriers to the Implementation of Incentives for Antibiotic Access and Innovation, Antibiotics
  29. ↑ Fleck-Vidal, Catherine; Doubell, Anna; Gerke, Christiane; Lamichhane, Usha; Ogilvie, Lesley; Sudbrak, Ralf; Kim, Jerome H.; Wartel, T. Anh; Plant, Laura (2025), Vaccines and AMR: An analysis of the funding landscape for human bacterial vaccines in low-and middle-income countries, Vaccine
  30. ↑ Lloyd, Czaplewski; Lamichhane, Usha; Sudbrak, Ralf; Hennessy, Alan; Ogilvie, Lesley; Piddock, Laura (2026), An overview of global public and philanthropic investments into antibacterial therapeutics (2017–23) (PDF), Lancet Microbe
  31. ↑ Piddock, Laura; Alimi, Yewande; Anderson, James; de Felice, Damiano; Moore, Catrin E.; Røttingen, John-Arne; Skinner, Henry; Beyer, Peter (2024), Advancing global antibiotic research, development and access (PDF), Nature Medicine
  32. ↑ Lloyd, Czaplewski; Lamichhane, Usha; Sudbrak, Ralf; Hennessy, Alan; Ogilvie, Lesley; Piddock, Laura (2026), An overview of global public and philanthropic investments into antibacterial therapeutics (2017–23) (PDF), Lancet Microbe
  33. ↑ Burki, Talha Khan (2018), A new alliance joins the fight against antimicrobial resistance, The Lancet Respiratory Medicine
  34. ↑ PPMI (2021), External Evaluation to monitor progress towards the objectives of the Global AMR R&D Hub, PPMI
Retrieved from "https://en.wikipedia.org/w/index.php?title=Global_AMR_R%26D_Hub&oldid=1353626176"